Skip to content
Scintria
ToolsGrant writerFunding
HomeLiteratureClinical trialsEvidence LabProtocol packData analysisLearnProjectsLibraryReferencesApplications
Start free
ScintriaStart free

Learn / Clinical Research Management / Foundations: ethics, GCP and the drug development pathway

ICH-GCP: the principles and the people

14 minute read · 6-question quiz

Download this lesson as a colour Word or PDF study guide with the figures and answers. Included in paid plans; reading and quizzes stay free.Sign in

What you will learn

  • Explain what Good Clinical Practice is and why it matters

  • State the main GCP principles

  • Describe the responsibilities of sponsor, investigator, monitor and ethics committee

Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve human participants. Compliance gives public assurance that participants' rights, safety and well-being are protected and that trial data are credible.

The standard is set by the International Council for Harmonisation (ICH) in the guideline E6. The widely used version is E6(R2), published in 2016. A modernised E6(R3), with a stronger focus on proportionate, risk-based approaches and quality by design, has been finalised, so teams should check which version their sponsor, regulator and country apply.

Core principles

  • Trials follow the ethical principles of the Declaration of Helsinki.
  • Risks are weighed against benefits; a trial starts only if benefits justify risks.
  • The rights, safety and well-being of participants prevail over the interests of science and society.
  • Available non-clinical and clinical information supports the planned trial.
  • The trial is scientifically sound and described in a clear protocol.
  • It is conducted in compliance with the protocol that received prior ethics approval.
  • Medical care is given by qualified physicians or dentists; each person involved is qualified by education, training and experience.
  • Freely given informed consent is obtained before participation.
  • All trial information is recorded, handled and stored so that it can be accurately reported, interpreted and verified.
  • Confidentiality of records is protected.
  • Investigational products are made and handled under Good Manufacturing Practice and used as in the protocol.
  • Systems with procedures that assure quality are implemented.
Protect peopleProtect dataInformed consentEthics approvalSafety monitoringConfidentialityFollow the protocolRecord accuratelyVerify and storeQuality systems
GCP has two aims: protect the people in the trial and protect the credibility of the data.

Roles and responsibilities

  • Sponsor: the person or organisation that takes responsibility for the initiation, management and financing of the trial. The sponsor designs the study, selects investigators, supplies product, ensures monitoring and safety reporting, and keeps quality systems. A sponsor may transfer duties to a contract research organisation (CRO), but remains ultimately responsible.
  • Investigator: the person responsible for the conduct of the trial at the site. The principal investigator (PI) may delegate tasks to qualified staff (delegation log) but remains responsible for participant welfare and data integrity.
  • Monitor (clinical research associate, CRA): the sponsor's or CRO's eyes at the site, verifying that rights and well-being are protected, data are accurate and the protocol is followed.
  • Research ethics committee (REC) or institutional review board (IRB): an independent body that reviews and approves the protocol, consent documents and investigators, and conducts continuing review.
  • Regulatory authority: approves or authorises trials, inspects sponsors and sites, and enforces the law. In Uganda this includes the National Drug Authority (NDA) for trials of medicines and vaccines.
  • Participants: volunteers whose rights come first.

Worked example: who is responsible for what?

During a monitoring visit, the CRA finds that a nurse took consent from three participants, but the delegation log does not list her for that task.

  • The investigator is responsible: tasks must be delegated before they are performed, and training documented.
  • The CRA records a protocol or GCP deviation, reports it to the sponsor and follows up.
  • The sponsor assesses whether the deviation is serious and whether the REC must be notified.
  • The REC reviews the deviation report and decides whether further action is needed to protect participants.

Corrective action includes retraining, updating the delegation log, and re-consenting participants if the consent was invalid. A root cause and a preventive action are recorded.

1SponsorDesign, fund, oversee2CRO / monitorDelegated duties3Investigator andsiteConduct the trial4ParticipantsRights come first
A simplified chain of responsibility. Ethics committees and regulators oversee every link.

Written, then done, then documented

GCP can be remembered as a three-part habit: say what you will do (protocol and procedures), do what you said, and document it so that someone else can verify it. "If it was not documented, it was not done."

Delegation is not abdication

Sponsors can transfer tasks to a CRO and investigators can delegate to staff, but neither can transfer ultimate responsibility. Oversight must be documented.

Check yourself

For a task at your site, such as consent or drug accountability, identify who is responsible, who is delegated, and where that delegation is documented.

Summary

  • GCP is the international quality standard for ethically and scientifically sound trials; ICH E6 defines it.

  • Its aims are to protect participants and to ensure credible data.

  • The sponsor, investigator, monitor, ethics committee and regulator each have defined duties.

  • Delegation of tasks must be documented, and responsibility cannot be delegated away.

Check your understanding

Question 1
1

ICH stands for:

Question 2
2

The ultimate responsibility for a trial's conduct at a site lies with the:

Question 3
3

A sponsor transfers duties to a CRO. Who remains ultimately responsible?

Question 4
4

A nurse performs consent but is not on the delegation log. This is a:

Question 5
5

Which body independently reviews and approves the protocol and consent documents?

Question 6
6

The GCP habit 'if it was not documented, it was not done' stresses:

Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.

The ethical foundations of clinical researchThe drug development pathway and trial phases